| Author | : Sigrid Sterckx |
| Publisher | : Cambridge University Press |
| Total Pages | : 375 |
| Release | : 2012-09-13 |
| Genre | : Business & Economics |
| ISBN | : 1107006945 |
This book provides the first comprehensive study of what cannot be patented and what should not be patentable in Europe.
| Author | : Australia. Law Reform Commission |
| Publisher | : Virago Press |
| Total Pages | : 690 |
| Release | : 2004 |
| Genre | : Genes |
| ISBN | : |
Report of an inquiry concerned with two broad issues: the patenting of genetic materials and technologies, and the exploitation of these patents and the distinction that can and possibly should be made between discoveries and inventions when referring to claims over genetic sequences.
| Author | : National Research Council |
| Publisher | : National Academies Press |
| Total Pages | : 186 |
| Release | : 2004-10-01 |
| Genre | : Science |
| ISBN | : 0309089107 |
The U.S. patent system is in an accelerating race with human ingenuity and investments in innovation. In many respects the system has responded with admirable flexibility, but the strain of continual technological change and the greater importance ascribed to patents in a knowledge economy are exposing weaknesses including questionable patent quality, rising transaction costs, impediments to the dissemination of information through patents, and international inconsistencies. A panel including a mix of legal expertise, economists, technologists, and university and corporate officials recommends significant changes in the way the patent system operates. A Patent System for the 21st Century urges creation of a mechanism for post-grant challenges to newly issued patents, reinvigoration of the non-obviousness standard to quality for a patent, strengthening of the U.S. Patent and Trademark Office, simplified and less costly litigation, harmonization of the U.S., European, and Japanese examination process, and protection of some research from patent infringement liability.
| Author | : Susy Frankel |
| Publisher | : |
| Total Pages | : |
| Release | : 2014-12 |
| Genre | : |
| ISBN | : 9781927183830 |
"The text will outline the history and rationale behind patent law, outline major areas of patent examination, and complexities, provide economic analysis, Maori and patent issues, international trade issues, and specialist patent court and tribunal issues"--Publisher information.
| Author | : Aggarwal, Rashmi |
| Publisher | : IGI Global |
| Total Pages | : 277 |
| Release | : 2017-06-30 |
| Genre | : Law |
| ISBN | : 1522524150 |
The growing presence of technology has created significant changes within the healthcare industry. With the ubiquity of these technologies, there is now an increasing need for more advanced legal procedures. Patent Law and Intellectual Property in the Medical Field is a pivotal reference source for the latest research in support of developing convergent and interoperable systems to increase awareness and applicability of legal aspects in the medical field. Featuring extensive coverage on relevant areas such as compulsory licensing, parallel importing, and protection law, this publication is an ideal resource for researchers, medical and law professionals, academics, graduate students, and practitioners engaged in medical practice.
| Author | : National Research Council |
| Publisher | : National Academies Press |
| Total Pages | : 457 |
| Release | : 1993-02-01 |
| Genre | : Political Science |
| ISBN | : 0309048338 |
As technological developments multiply around the globeâ€"even as the patenting of human genes comes under serious discussionâ€"nations, companies, and researchers find themselves in conflict over intellectual property rights (IPRs). Now, an international group of experts presents the first multidisciplinary look at IPRs in an age of explosive growth in science and technology. This thought-provoking volume offers an update on current international IPR negotiations and includes case studies on software, computer chips, optoelectronics, and biotechnologyâ€"areas characterized by high development cost and easy reproducibility. The volume covers these and other issues: Modern economic theory as a basis for approaching international IPRs. U.S. intellectual property practices versus those in Japan, India, the European Community, and the developing and newly industrializing countries. Trends in science and technology and how they affect IPRs. Pros and cons of a uniform international IPRs regime versus a system reflecting national differences.
| Author | : Phillip Johnson |
| Publisher | : Butterworths |
| Total Pages | : 2624 |
| Release | : 2018-12-17 |
| Genre | : |
| ISBN | : 9781474310321 |
Written by some of the most eminent IP practitioners, The Modern Law of Patents offers a fresh, and comprehensive exposition of the law relating to patents in the UK and Europe, including before the Unified Patent Court.Updates in the new fourth edition will include:* Supreme Court's decision in Eli Lilly v Actavis [2017] UKSC 48 and the revival of a doctrine of equivalents;* The new threats provisions under the Intellectual Property (Unjustified Threats) Act 2017 and its relationship to malicious prosecution following Willers v Joyce [2016] UKSC 43;* Declarations of obviousness: Fujifilm Kyowa Kirin Biologics v Abbvie Biotechnology Ltd [2017] EWCA Civ* The effect on employee compensation following Shanks v Unilever [2017] EWCA Civ 2;* The Unitary Patent Court, including the Protocol on provisional applications (PPA) and the most recent (18th) draft of the Rules of Procedure;* Developments in IPEC practice, including the costs ramifications of PPL v Hagan [2016] EWHC 3076 (IPEC) [although there is talk of this being reversed by an amendment to the CPR];* The developments in cases on damages and account of profits case law* Standards Patents and FRAND damages: Unwired Planet International Ltd v Huawei Technologies Co. Ltd & Anor [2017] EWHC 711 (Pat)* Settlements and competition law: T-472/13 Ludbeck ECLI:EU:T:2016:449 (on appeal C-591/16).* An exploration of the likely effects of Brexit on patent law;* All the developments in practice under the Patents Act 1977, the Patent Cooperation Treaty and at the European Patent Office.
| Author | : Ellen F. M. 't Hoen |
| Publisher | : |
| Total Pages | : 181 |
| Release | : 2016 |
| Genre | : |
| ISBN | : 9789079700851 |
Millions of people around the world do not have access to the medicines they need to treat disease or alleviate suffering. Strict patent regimes introduced following the establishment of the World Trade Organization in 1995 interfere with widespread access to medicines by creating monopolies that keep medicines prices well out of reach for many. 0The AIDS crisis in the late nineties brought access to medicines challenges to the public?s attention, when millions of people in developing countries died from an illness for which medicines existed, but were not available or affordable. Faced with an unprecedented health crisis ? 8,000 people dying daily ? the public health community launched an unprecedented global effort that eventually resulted in the large-scale availability of low-priced generic HIV medicines. 0But now, high prices of new medicines - for example, for cancer, tuberculosis and hepatitis C - are limiting access to treatment in low-, middle and high-income countries alike. Patent-based monopolies affect almost all medicines developed since 1995 in most countries, and global health policy is now at a critical juncture if the world is to avoid new access to medicines crises. 0This book discusses lessons learned from the HIV/AIDS crisis, and asks whether actions taken to extend access and save lives are exclusive to HIV or can be applied more broadly to new global access challenges.
| Author | : National Research Council |
| Publisher | : National Academies Press |
| Total Pages | : 189 |
| Release | : 2006-04-09 |
| Genre | : Science |
| ISBN | : 0309100674 |
The patenting and licensing of human genetic material and proteins represents an extension of intellectual property (IP) rights to naturally occurring biological material and scientific information, much of it well upstream of drugs and other disease therapies. This report concludes that IP restrictions rarely impose significant burdens on biomedical research, but there are reasons to be apprehensive about their future impact on scientific advances in this area. The report recommends 13 actions that policy-makers, courts, universities, and health and patent officials should take to prevent the increasingly complex web of IP protections from getting in the way of potential breakthroughs in genomic and proteomic research. It endorses the National Institutes of Health guidelines for technology licensing, data sharing, and research material exchanges and says that oversight of compliance should be strengthened. It recommends enactment of a statutory exception from infringement liability for research on a patented invention and raising the bar somewhat to qualify for a patent on upstream research discoveries in biotechnology. With respect to genetic diagnostic tests to detect patient mutations associated with certain diseases, the report urges patent holders to allow others to perform the tests for purposes of verifying the results.
